Evaluation of Viral Replication by Tonate Virus (TONV) and Zika Virus (ZIKV), Within an ex Vivo Trophoblast and Placental Model
NCT05589012 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 8
Last updated 2022-10-21
Summary
Prospective, non-interventional study carried out after culturing placental trophoblastic tissue ex vivo and infection with Zika and Tonate
Conditions
- Zika Virus Infection
Interventions
- BIOLOGICAL
-
Cell line and virus
C6/36 cells will be cultured in L15 culture medium (Leibovitz's L-15 medium), supplemented with 5% FBS (Fetal Bovine Serum) and 1% penicillin/streptomycin at 28°C in a humidified atmosphere containing 5% C02. ZIKV and TONV will be expanded and titrated using C6/36 cells. The viral stock will be aliquoted in 100 µL aliquots and stored at -80°C.
- BIOLOGICAL
-
Infection of human placental culture explants
Placental tissues will be handled within one hour of delivery. The chorionic villi will be dissected into 5mm sections and the tissues washed abundantly, minimum 3 times with a standard culture medium (RPMI-1640 supplemented with 10% heat-inactivated fetal calf serum (FCS), 1% L-Glutamine and 1% Penicillin/Streptomycin) to remove maternal blood, membranes and blood clots. Collagen gel sponges will be placed in 6-well plate wells containing 3mL of culture medium (RPMI-1640 supplemented with 15% heat-inactivated fetal bovine serum (FCS), 1% Penicillin/streptomycin, 0 1% Gentamycin, 1% Amphotericin B, 1% L-Glutamine, 1% non-essential amino acid, 1% sodium pyruvate) per well. Chorionic villi will be dissected into 5mm sections and placed on top of collagen gel sponges at the interface between culture medium and air.
- BIOLOGICAL
-
Determination of viral load in tissues by qRT-PCR
The tissues will be lysed by mechanical disruption in a lysis buffer + 4%TCEP (Tris(2-carboxyethyl)phosphine hydrochloride) (Machery-Nagel ref: 740395.107) with the Precellys system. The lysed tissues will be diluted in 100 mg/mL of Macherey-Nagel lysis buffer, aliquoted and stored at -80°C until extraction. Total RNA will be extracted in duplicate using the Nucleospin 96 RNA Core kit (Macherey Nagel ref: 740466.4), following the supplier's instructions. Standard samples, controls and ZIKV and TONV viral RNA will be extracted and tested in parallel under the same conditions. The extracted RNA will be subjected to reverse transcriptase, using the Superscript One-Step RT-qPCR kit (Invitrogen ref: 11732088) according to the manufacturer's recommendations, with a probe and primer specific for ZIKV and TONV.
Sponsors & Collaborators
-
Assistance Publique - Hôpitaux de Paris
lead OTHER
Eligibility
- Min Age
- 18 Years
- Sex
- FEMALE
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2023-11-01
- Primary Completion
- 2024-04-01
- Completion
- 2024-04-01
More Related Trials
-
Assessment of Obstetric, Fetal and Neonatal Risks and Vertical SARS-CoV-2 Transmission During COVID-19 Pandemic
NCT04360811 ·Status: COMPLETED ·Phase: NA
-
Against Chikungunya Virus and Neonatal Infection
NCT07190560 ·Status: RECRUITING ·Phase: NA
-
Estimated Cumulative Incidence of Zika Infection at the End of the First Epidemic in the French West Indies in a Sample of Patients Followed for HIV Infection.
NCT03161444 ·Status: TERMINATED ·Phase: NA
-
Lyon Cohort of Maternal and Congenital Toxoplasma Infections
NCT02936921 ·Status: RECRUITING
-
Comparing Infectious Morbidity Among Women With Meconium-stained Amniotic Fluid at Term, Between Those Treated With Prophylactic Antibiotics Zinacef vs. Placebo
NCT06849037 ·Status: RECRUITING ·Phase: NA
-
Study of Viral Load and Maternal-fetal Serology in the Interpretation of the Vertical Transmission of SARS Cov-2 (COVID-19) During Pregnancy
NCT04402918 ·Status: COMPLETED ·Phase: NA
-
Maternal- Fetal Infection
NCT03371056 ·Status: COMPLETED ·Phase: NA
-
Analysis of Cerebrospinal Fluid in Patients With Cerebral Toxoplasmosis at CHSD (2004-2024)
NCT07044037 ·Status: COMPLETED
-
Assessment of Two Therapeutic Strategies in the Treatment of Children With Congenital Toxoplasmosis
NCT01202500 ·Status: TERMINATED ·Phase: PHASE3
-
Evaluating Clinical Parameters of COVID-19 in Pregnancy
NCT04470583 ·Status: UNKNOWN
-
Transplacental Transmission of COVID-19
NCT05124574 ·Status: TERMINATED
-
ZIKAlliance Children Cohort (ZIKAllianceCH)
NCT03393286 ·Status: COMPLETED
-
Study of Maternal Hepatitis C Infection and Influenza Vaccination in Pregnancy
NCT00810875 ·Status: TERMINATED
-
Rapid Molecular Diagnosis and Detection of Emerging Infectious Diseases in Patients With Tropical Fever (Tropifever)
NCT06539325 ·Status: RECRUITING ·Phase: NA
-
Biomarkers of Cytomegalovirus Fetal Infection and Disease
NCT03090841 ·Status: UNKNOWN
-
Study of the Prevalence of Cosavirus and Salivirus Infections, Two New Genera of Picornaviridae, In Infants
NCT02862847 ·Status: COMPLETED
-
Detection of Human Cytomegalovirus in the Saliva
NCT00815802 ·Status: COMPLETED
-
Prevalence and Impact of COVID-19 Infection in Pregnant Women, Fetuses and Newborns
NCT04355234 ·Status: COMPLETED ·Phase: NA
-
Efficacy Study of Preconception Treatment of an Asymptomatic Bacterial Infection in an Infertility Population
NCT01322971 ·Status: TERMINATED ·Phase: NA
-
Diagnosis of Toxoplasma Gondii Infection by Exploration of Cellular Immunity (TOXCELL)
NCT04825600 ·Status: COMPLETED ·Phase: NA
-
Identification and Clinical Validation of Biomarkers Associated With Clinical Severity in Adults Infected With RSV
NCT06197152 ·Status: RECRUITING
-
TT-CMV Observational Birth Cohort Study
NCT00907686 ·Status: COMPLETED
-
Pregnant Women Vaccinated Against Covid-19.
NCT04957953 ·Status: COMPLETED
-
Isolated Positive Toxoplasma Gondii PCR in Blood
NCT07054918 ·Status: NOT_YET_RECRUITING
-
Cytomegalovirus (CMV) Infection in Amniotic Fluid
NCT00194142 ·Status: COMPLETED